The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Does Serotonin Augmentation Have Any Effect on Cognition and Activities of Daily Living in Alzheimer's Dementia?: A Double-Blind, Placebo-Controlled Clinical Trial
Abstract
Objective Recent studies suggest that cholinergic dysfunction does not provide a complete account of age-related cognitive deficits, and other neuronal systems like monoaminergic hypofunction are involved. In several studies, selective serotonin reuptake inhibitors demonstrated promotion in neurogenesis in the hippocampus and enhanced memory and cognition. The aim of this study is to survey the effect of serotonin augmentation on cognition and activities of daily living in patients with Alzheimer's disease. Method The trial was designed as a 12-week randomized, placebo-controlled, double-blind study. One hundred twenty-two patients aged 55 to 85 years with mild-to-moderate Alzheimer's dementia were randomly allocated in 1 of the 3 treatment groups: fluoxetine plus rivastigmine, rivastigmine alone, or placebo group. Efficacy measures comprised assessments of cognition, activities of daily living, and global functioning. Hamilton Depression Scale also was used to assess changes in mood throughout the study. Result Fluoxetine plus rivastigmine and rivastigmine groups demonstrated improvement on measures of cognitive and memory without any significant difference; however, the former group did better in their activities of daily living and global functioning. Patients taking placebo had significant deterioration in all the efficacy measures. Patients taking rivastigmine or rivastigmine plus fluoxetine had improvements in Hamilton Depression Scale without significant differences. C…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the majority of cases reported, antidepressants had the same effect on cognition as placebo.
“In the majority of the cases reported, antidepressants had the same effect on cognition as placebo [44–47]”
From Antidepressant use and cognitive decline in patients with dementia: a national cohort study (2025) · cites this paper as [46]
Previous studies of antidepressant use and cognitive decline in people with dementia have shown mixed findings.
“Previous studies of antidepressant use and cognitive decline in people with dementia have shown mixed findings.”
From Antidepressant use and cognitive decline in patients with dementia: a national cohort study (2025) · cites this paper as [46]
Citations
Cites
Adult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964
Hayward, G., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.016 · Cited by 162
Flagged first, then by citations
Research works printed but not linked: 26
- Meltze, 1998, Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging., Neuropsychopharmacology, 18, 407, 10.1016/S0893-133X(97)00194-2 · DOI
- Wenk, 1989, Age related changes in multiple neurotransmitter systems in the monkey brain., Neurobiol Aging, 10, 11, 10.1016/S0197-4580(89)80005-3 · DOI
- Palmer, 1993, Monoamine neurons in aging and Alzheimer's disease., J Neural Transm, 91, 135, 10.1007/BF01245229 · DOI
- Rossor, 1986, Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease., Br Med Bull, 42, 70, 10.1093/oxfordjournals.bmb.a072101 · DOI
- Decker, 1991, The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory., Synapse, 7, 151, 10.1002/syn.890070209 · DOI
- Riekkinen, 1994, Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behavior., Brain Res, 649, 174, 10.1016/0006-8993(94)91061-8 · DOI
- Lai, 2002, Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease., Neuroreport, 13, 1175, 10.1097/00001756-200207020-00021 · DOI
- Newhouse, 2002, Alzheimer's disease, serotonin system and tryptophan depletion., Am J Geriatr Psychiatry, 10, 483, 10.1097/00019442-200207000-00019 · DOI
- Abe, 2003, Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease., J Pharmacol Sci, 93, 95, 10.1254/jphs.93.95 · DOI
- Erkinjuntti, 1993, Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease., Arch Neurol, 50, 305, 10.1001/archneur.1993.00540030069017 · DOI
- Gould, 1997, Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation., J Neurosci, 17, 2492, 10.1523/JNEUROSCI.17-07-02492.1997 · DOI · Paper page
- Manev, 2001, Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus., Eur J Pharmacol, 1, 420
- Malberg, 2000, Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus., J Neurosci, 20, 9104, 10.1523/JNEUROSCI.20-24-09104.2000 · DOI · Paper page
- Vermetten, 2003, Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder., Biol Psychiatry, 54, 693, 10.1016/S0006-3223(03)00634-6 · DOI · Paper page
- Vythilingam, 2004, Hippocampus volume, memory, and cortical status in major depressive disorder: effects of treatment., Biol Psychiatry, 56, 101, 10.1016/j.biopsych.2004.04.002 · DOI · Paper page
- Schmitt, 2006, Serotonin and human cognitive performance., Curr Pharm Des, 12, 2473, 10.2174/138161206777698909 · DOI
- Reisberg, 1988, Brief Cognitive Rating Scale (BCRS)., Psychopharmacol Bull, 24, 629
- Hachinski, 1975, Cerebral blood flow in dementia., Arch Neurol, 32, 632, 10.1001/archneur.1975.00490510088009 · DOI · Paper page
- Hamilton, 1967, Development of a rating scale for primary depressive illness., Br J Soc Clin Psychol, 6, 278, 10.1111/j.2044-8260.1967.tb00530.x · DOI
- Folstein, 1975, Mini-Mental State: a practical method for grading the cognitive state of patients for clinicians., J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- Iverson, 2001, Interpreting change on the WAIS-III/WMS-III in clinical samples., Arch Clin Neuropsychol, 16, 183, 10.1093/arclin/16.2.183 · DOI
- Lawton, 1969, Assessment of older people: self-maintaining and instrumental activities of daily living., Gerontologist, 9, 179, 10.1093/geront/9.3_Part_1.179 · DOI · Paper page
- Balesteri, 2002, Behavioral and psychological symptoms of dementia as a risk factor for nursing home placement., Int Psychogeriatr, 12, 59, 10.1017/S1041610200006773 · DOI
- Patterson, 1992, Assessment of functional ability in Alzheimer's disease: a review and a preliminary report on the Cleveland Scale for Activities of Daily Living., Alzheimer Dis Assoc Disord, 6, 145, 10.1097/00002093-199206030-00003 · DOI
- Proctor, 1992, Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms., Neurochem Res, 17, 917, 10.1007/BF00993268 · DOI
- Morretti, 2002, Depression and Alzheimer's disease: symptom or comorbidity?, Am J Alzheimers Dis Other Demen, 17, 338, 10.1177/153331750201700607 · DOI
Cited by
Sorted by citations
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Pietrzak, R. H., Lim, Y. Y., Neumeister, A., Ames, D., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Restrepo, C., Martins, R. N., Masters, C. L., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2476 · Cited by 214
Prado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
Kessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.020 · Cited by 113
Xie, Y., Liu, P.-P., Lian, Y.-J., Liu, H.-B., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0064-7 · Cited by 49
Antidepressant use and cognitive decline in patients with dementia: a national cohort study
Mo, M., Abzhandadze, T., Hoang, M. T., Sacuiu, S., Jurado, P. G., Pereira, J. B., Naia, L., Kele, J., Maioli, S., Xu, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03851-3 · Cited by 45
Metadata
- Authors
- Mowla, A., Mosavinasab, M., Haghshenas, H., & Haghighi, A. B.
- Affiliations
- Shiraz University of Medical Sciences (IR)
- Corresponding author
- Mowla, Arash
- Mosavinasab, Masoud
- ORCID
- Mowla, Arash
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-10
- Volume
- 27
- Issue
- 5
- Pages
- 484-487
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1982388019
- Cited by
- 116
- References
- 2
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 5 · 2023: 4 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 10 · 2017: 2 · 2016: 10 · 2015: 13 · 2014: 10 · 2013: 1 · 2012: 10
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, fluoxetine, rivastigmine, acetylcholinesterase inhibitors, combination therapy, cognitive impairment, activities of daily living, global functioning, depression
- MeSH terms
- Rivastigmine, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Analysis of Variance, Cholinesterase Inhibitors, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics, Severity of Illness Index, Selective Serotonin Reuptake Inhibitors, Phenylcarbamates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
